Ropes & Gray represented Viridian Therapeutics in an exclusive licensing and collaboration deal with Kissei Pharmaceutical to develop and market thyroid eye disease therapy veligrotug and VRDN-003 in Japan. The transaction was announced on July 30.
Under the agreement, Viridian will receive a $70 million upfront payment with potential to receive an additional $315 million in milestone payments as well as tiered royalties on net sales in Japan.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associates Nicole Rohr and Ryan Kramer and included tax partner David Saltzman.
